Cardiac sympathetic activity is increased in patients with myocardial infarction, 1 unstable ischemic heart disease, 2 stress-induced cardiomyopathy, 3 and congestive heart failure. 4 Excessive cardiac sympathetic drive exacerbated by standing is the leading feature of postural tachycardia syndrome (POTS). 5 Conversely, cardiac parasympathetic regulation assessed through heart rate (HR) variability and baroreflex testing is impaired in congestive heart failure, 6,7 after myocardial infarction, 8 and in POTS. 9 Treatments addressing autonomic imbalance, including β-blockers in patients and chronic electrical vagus nerve stimulation in animals, 10 improve survival. In the sinus node, sympathetic and parasympathetic influences are integrated through hyperpolarization-activated and cyclic nucleotide-gated 4 (HCN4) channels producing "funny" or pacemaker currents (I(f)). 11 The current determines the diastolic depolarization slope of sinus node pacemaker cells, thereby setting HR. Intracellular cyclic adenosine monophosphate (cAMP) regulates HCN4 12 such that β-adrenergic stimulation augments, and cholinergic stimulation attenuates, channel conductivity. Thus, HCN4 comprises the final common pathway for autonomic HR regulation, providing a physiological basis for selective HCN4 blockade with ivabradine in the treatment of heart failure 13 and angina pectoris. 14 Yet how pharmacological HCN4 inhibition affects human autonomic cardiovascular control, particularly in the setting of increased cardiac sympathetic drive, is poorly understood. Studies in mice with inducible cardiac-specific HCN4 deletion 15 and in patients with mutations rendering HCN4 cAMP-insensitive 12 suggest that the channel may be more important for rhythm control at lower HRs. HR responses to adrenergic stimulation are surprisingly maintained. Yet selective sinus rhythm modulation leaves myocardial responses to adrenergic stimulation unopposed. Therefore, we tested the hypothesis that pharmacological HCN4 inhibition attenuates HR in a human model of severe cardiac sympathetic activation. Sympathetic activation was achieved by selective norepinephrine reuptake inhibition combined with graded orthostatic stress.
RESULTSWe screened 63 men. Twenty-four subjects fulfilled all inclusion and exclusion criteria and entered the study. Nineteen men completed all three study visits and were included in the analysis Hyperpolarization-activated, cyclic nucleotide-gated 4 (HCN4) channels comprise the final pathway for autonomic heart rate (HR) regulation. We hypothesized that HCN4 inhibition could reverse autonomic imbalance in a human model of cardiac sympathetic activation. Nineteen healthy men ingested oral metoprolol+reboxetine, ivabradine+reboxetine, or placebo+reboxetine in a double-blind, randomized, crossover fashion. We assessed HR, blood pressure (BP), stroke volume, and cardiac output during rest and profound orthostatic stress. HR variability, BP variability, and baroreflex sensitivity were analyzed. Metoprolol, but not ivabradine, decreased resting HR...